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Abstract
Background: Non-small cell lung cancer (NSCLC) is a heterogeneous group of disorders with a number of genetic and
proteomic alterations. c-CBL is an E3 ubiquitin ligase and adaptor molecule important in normal homeostasis and cancer. We
determinedthegeneticvariationsofc-CBL,relationshiptoreceptortyrosinekinases(EGFRandMET),andfunctionalityinNSCLC.
Methods and Findings: Using archival formalin-fixed paraffin embedded (FFPE) extracted genomic DNA, we show that
c-CBL mutations occur in somatic fashion for lung cancers. c-CBL mutations were not mutually exclusive of MET or EGFR
mutations; however they were independent of p53 and KRAS mutations. In normal/tumor pairwise analysis, there was
significant loss of heterozygosity (LOH) for the c-CBL locus (22%, n=8/37) and none of these samples revealed any mutation
in the remaining copy of c-CBL. The c-CBL LOH also positively correlated with EGFR and MET mutations observed in the
same samples. Using select c-CBL somatic mutations such as S80N/H94Y, Q249E and W802* (obtained from Caucasian,
Taiwanese and African-American samples, respectively) transfected in NSCLC cell lines, there was increased cell viability and
cell motility.
Conclusions: Taking the overall mutation rate of c-CBL to be a combination as somatic missense mutation and LOH, it is
clear that c-CBL is highly mutated in lung cancers and may play an essential role in lung tumorigenesis and metastasis.
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Introduction
In the US alone, each year approximately 219,400 people are
diagnosed with lung cancers, out of which more than 145,000 of
them succumb to the disease [1]. This number is roughly equivalent
to the combined mortality rates of cancers of the breast, prostate,
colon, liver, kidney and melanoma [1]. In addition the prognosis is
usually poor and the five-year survival rate is less than 15%. There
are also significant ethnic differences for lung cancer, and the
outcome is worse for blacks compared to whites. Gender differences
are also striking with women having significantly better prognosis as
compared to men. There are a number of genetic alterations that
can occur in lung cancer. As an example, in NSCLC, mutations in
KRAS, p53, EGFR and MET have been identified. Many of these
pathways, especially Receptor Tyrosine Kinases (RTKs) are
controlled by c-CBL.
CBL (Casitas B-lineage lymphoma) is a mammalian gene
located on human chromosome 11q23.3 [2] and is involved in
cell signaling and protein ubiquitination [3]. CBL proteins belong
to the RING finger class of ubiquitin ligases (E3) and there are
three homologues c-CBL, CBL-b, CBL-3 [4]. The c-CBL and
CBL-b genes are ubiquitously expressed with the highest levels in
hematopoietic tissues [5]. c-CBL consists of four regions encoding
for functionally distinct protein domains: the N-terminal tyrosine
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RING finger domain, the proline-rich region and the c-terminal
ubiquitin-associated (UBA) domain that also overlaps with a
leucine-zipper (LZ) domain [3]. Both TKB and RING finger
domains are essential for ligand-induced ubiquitination of RTKs
[6,7,8,9]. The RING finger domain is required for the recruitment
of E2 ubiquitin-conjugating enzymes. The TKB domain includes
four-helix bundle (4H), a calcium-biding EF hand, and a modified
SH2 domain, which binds to phosphotyrosine residues
[3,10,11,12]. In addition, the proline-rich region of c-CBL can
associate with the SH3 domain of Grb2, which can indirectly
recruit c-CBL to RTKs via the GRB2 adaptor protein [7,13,14].
c-CBL also binds to EGFR and acts as the E3 that targets
EGFR for ubiquitination and degradation. Furthermore, CBL
desensitizes EGF signaling and opposes cellular proliferation
induced by EGF [15]. EGF activation also appears to activate
the tyrosine kinase SRC, which phosphorylates c-CBL and in turn
activates the ubiquitination and degradation of EGFR [16,17,18].
A recent study shows that defective endocytosis of EGFR is
characterized by a deletion mutant and the point mutation
L858R, whereby its association with c-CBL and subsequent
ubiquitination are impaired [19]. Recently, the first human c-CBL
mutations were reported in acute myeloid leukemia (AML)
patients [20]. The mutation R420Q inhibits FMS-like tyrosine
kinase 3 (FLT3) internalization and ubiquitination [20].
Not only can E3 activity be important in oncogenesis, c-CBL has
a dual but separate function as a signal transduction molecule. We
have previously shown that c-CBL is important in binding CRKL
and BCR/ABL in hematopoietic cells. Also, it can bind and
modulate functions of cytoskeleton by binding to proteins like talin
and paxillin. The TKB domain is important in binding to a number
of molecules, and they then function in signal transduction.
Given the critical role of CBL in normal homeostasis and
cancer, we hypothesized that it might be mutated in lung cancers.
In this study, we report novel c-CBL somatic mutations S80N/
H94Y, Q249E and W802* in Caucasian, Taiwanese and African-
American lung cancer patients, respectively. Expressing these
mutations in NSCLC cell lines lead to increased proliferation and
cell motility. We show that c-CBL mutations occur with or without
MET or EGFR mutations but are mutually exclusive of a LOH at
the c-CBL locus. Additionally, c-CBL LOH is associated with
either MET or EGFR mutations. We thus hypothesize that c-CBL
mutations might contribute to the oncogenic potential of MET
and EGFR in lung cancer.
Methods
Ethics Statement
Written consent on all research on human subjects has been
obtained from the Institutional Review Board, University of
Chicago and covers all research performed in the laboratory. The
following is their contact information: Institutional Review Board,
The University of Chicago, McGiffert Hall, 5751 S. Woodlawn
Ave., 2nd floor, Chicago, IL 60637. Written informed consents
were received from all patients whose tissue samples were used for
this study.
Tissue Samples
Lung cancer tissue and paired adjacent normal lung tissues
were obtained from 50 Caucasian, 29 African-Americans and 40
Taiwanese NSCLC patients who were recruited at the University
of Chicago Hospital (Chicago, USA) (Caucasian and African-
American patients) and Taipei Veterans General Hospital of
Taiwan (Taiwanese patients) after obtaining appropriate Institu-
tional Review Board permission and informed consent from the
patients. Out of 119 samples, 77 were men, 38 were women and 4
were unknown with age at diagnosis ranging from 47 to 90 years.
In terms of tumor types, 53 were adenocarcinoma, 32 were
squamous cell carcinoma and 34 were large cell carcinoma. 49
were stage I, 14 were stage II, 34 were stage III, and 13 were stage
IV (Table S1).
Cell Culture
Human non-small cell lung carcinoma cells A549 and H358
were maintained in DMEM and RPMI-1640, respectively.
Human embryonic kidney 293T cells were cultured in DMEM.
Media were supplemented with 10% fetal bovine serum, 100
units/ml of penicillin, and 100 mg/ml of streptomycin (Invitrogen,
Carlsbad, CA). Cells were cultured at 37uC in a humidified
incubator containing 5% CO2.
c-CBL Gene Mutational Analysis
Exons 2 to 16 of c-CBL gene were individually amplified by
polymerase chain reaction (PCR). Primers are listed in Table S2.
PCR conditions were 1 cycle of 95uC for 5 minutes; 35 cycles of
94uC for 30 seconds, 58uC for 30 seconds and 72uC for 2 minutes;
and one cycle of 72uC for 10 minutes. PCR products were
treated with ExoSAP-IT (USB Corporation, Cleveland, OH) and
sequenced by Big-Dye Terminator Chemistry (Applied Biosys-
tems, Foster City, CA). Sequencing was performed on the forward
coding strand with confirmation of c-CBL alterations performed by
sequencing the reverse strand as well. Chromatograms were
analyzed for mutations using Mutation Surveyor v2.61 (Soft-
genetics, State College, PA).
Plasmid Constructs and Site-Directed Mutagenesis
The wild-type c-CBL cDNA insert was subcloned into the
pAlterMax expression vector using XhoI and SalI restriction
enzyme sites (Promega, Madison, WI). Using this parental
plasmid pAlterMax-c-CBL, the TKB domain double mutation
(S80N/H94Y), the point mutation (Q249E), and the C-termi-
nal point mutation W802* of c-CBL were created using the
following primers: 59-GCTGGCGCTAAAGAATAACCCACC-
TTATATCTTAGAC-39 and 59-CTACCAGATACCTACCAG-
TATCTCCGTACTATCTTGTC-39 for the double mutation
S80N/H94Y; 59-CTTTACCCGACTCTTTGAGCCCTGGTC-
CTCTTTGC-39 for Q249E, and 59-CAGCTCCTCCTTTG-
GCTGATTGTCTCTGGATGGTGATC-39 for W802* along
with their complementary primers using the QuickChange Site-
Directed Mutagenesis XL kit (Stratagene, La Jolla, CA) according
to the manufacturer’s instructions. The constructs were confirmed
for the point mutations by standard DNA sequencing of both
strands.
Loss of Heterozygosity (LOH) Analysis
Five microsatellites on chromosome 11 (3 on 11q at or within
200 kb up or downstream of the c-CBL gene and 2 control markers
on 11p) were selected for analysis (Table S3). Established
microsatellite markers and respective primer sequences were selected
from the GeneLoc database (http://genecards.weizmann.ac.il/
geneloc/index.shtml, Weizmann Institute of Science, Rehovot,
Israel). Primers were custom designed and each forward primer
was fluorescently labeled at the 59 end with FAM, PET, NED, or
VIC (Applied Biosystems). Primer annealing temperatures and
duplex scores were evaluated with NIST Primer Tools (http://
yellow.nist.gov:8444/dnaAnalysis/primerToolsPage.do; National In-
stitute of Standards and Technology, Gaithersburg, MD). Primers
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TK6 cells) and resolving the products on agarose gels. Bands were
visualized with an UV transilluminator. Genomic DNA was
extracted from tumor samples and paired normal lung tissue. Primers
were grouped into multiplex combinations shown in Table S4.
Marker D11S929 served as an internal control to check for
consistency in PCRs and of peaks from capillary electrophoresis.
Multiplex PCRs were carried out in a volume of 10 mLt h a t
contained 1 mL genomic DNA (20–50 ng), 0.5 mM of each primer
(1.0 mM total for each primer pair), 400 mM dNTPs, 1X PCR buffer
containing MgCl2,a n d0 . 2UTaq DNA polymerase. PCR was
performed on the ABI GeneAmp 9700 PCR System under the
following conditions: 5 min at 94uC; 30 cycles of 30 sec at 94uC,
1m i na t6 0 uC, 1 min at 72uC; and 5 min at 72uC. The PCR
products were separated by capillary electrophoresis on an ABI
3130XL DNA Analyzer. Chromatograms were analyzed with Peak
Scanner 1.0 and GeneMapper 3.7 software (Applied Biosystems) for
allelic alterations. The area of the peaks produced by the DNA PCR
products was quantified for each allele. The ratio of the allelic areas
was calculated for each tumor and paired normal DNA sample.
When the qLOH (allelic ratio for the tumor peaks divided by the
allelicratioofpairednormalsample)was#0.5 or $2.0for c-CBLand
atleastoneother11qmarkerinatleasttwoseparateexperiments,the
sample was considered as having an allelicimbalance and interpreted
asLOH.Sampleswere evaluated in at least two separate experiments
and samples showing prospective LOH at c-CBL repeated a third
time which included a new control marker at the BAX locus (data not
shown) on chromosome 19 to verify integrity of sample DNA.
Transfection of c-Cbl Constructs
The A549 cell line was transfected using the Fugene HD
(Roche, Nutley, NJ) reagent according to the manufacturer’s
instructions. Eight mg of plasmid DNA, containing either no insert
(empty vector), wild-type c-CBL, S80N/H94Y c-CBL, Q249E c-
CBL or W802* CBL was used for transfection in a 6-well culture
plate. Cells were harvested 48 h after transfection and analyzed for
expression.
c-CBL Knockdown
c-CBL knockdown was performed using lentiviral transduction
using MISSION lentiviral transductionparticles(Sigma-Aldrich,St.
Louis,MO)aspermanufacturer’sinstructions.Briefly,1610
5 H358
cells/wellwere seededin6-wellplatesandinfectedthefollowingday
with c-CBL lentiviral shRNA constructs. To generate stable c-CBL
knockdown cell lines, cells were selected for 2 days with 1 mg/ml
puromycin. c-CBL levels were determined using whole cell lysates
by immunoblotting with anti-CBL antibody (Santa Cruz Biotech-
nologies, Santa Cruz, CA).
Cell Viability Assay
Cells were transfected as described above in the transfection
assay. Forty-eight hours after transfection, viability of cells was
assessed using Trypan Blue exclusion.
Wound Healing Assay
A549 cells were seeded in 6-well plates and cultured for 48 h
until 100% confluent. The medium was then changed and the cells
were transfected as described in the transfection assay. Twelve
hours after transfection, a straight scratch was made across the cell
layer using a 1 ml pipette tip. The cells were then gently washed
with 16 PBS to remove cellular debris and the media was
replaced. Photographs were taken of the wound region every 12 h
until 48 h.
Western Blot Analysis
Forty eight hours after transfection, cells were collected and
washed twice in 1X PBS, then lysed in ice-cold lysis buffer (0.5M
Tris-HCl with pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid,
10 mM EDTA, 10% NP-40, 0.5 mM DTT, 1 mM phenylmethyl-
sulfonyl fluoride, 5 mg/mL leupeptin, and 10 mg/mL aprotinin)
for 5 minutes. The lysate was centrifuged at 13,000 rpm for
20 minutes at 4uC, and protein content of the supernatant was
measured. Total cell lysates (50 mg/well) were separated by SDS-
PAGE electrophoresis and the gels transferred onto nitrocellulose
membranes (Whatman, Piscataway, NJ). Membranes were
blocked with 5% non-fat dry milk in phosphate-buffered saline
containing Tween-20 (PBST) (1X PBS, 0.1% Tween-20) for 1 h at
room temperature and incubated with the appropriate primary
antibody at 4uC overnight. Membranes then were washed three
times with PBST and probed with appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody for 1 h at room
temperature. The membranes were again washed three times in
PBST and bands were visualized using Western blot chemilumi-
nescence reagent (BioRad, Valencia, CA) on a Chemidoc Gel
documentation system (BioRad, Valencia, CA). Antibodies were
obtained from Santa Cruz Biotechnologies and used at the
following dilutions (c-CBL, 1:5000; c-MET, 1:5000; EGFR,
1:5000; ubiquitin, 1:1000; HA, 1:5000 and b-actin, 1:10,000).
Flow Cytometry
Cell cycle analysis was carried out by flow cytometry.
Approximately 2610
6 cells were grown in media containing
10% FBS. Cells were harvested by trypsin/EDTA treatment,
washed with 1X PBS three times and fixed with ice-cold 70%
ethanol for 2 h. Cells were washed again with cold PBS and
stained with a solution containing 25 mg/mL propidium iodide,
200 mg/mL RNase A, and 0.1% Triton X-100 for 30 minutes in
the dark. Cell cycle analysis was performed using a Guava PCA-96
flow cytometer (Guava Technologies, Millipore, Billerica, MA).
Ubiquitin Ligase Activity
293T cells were maintained in culture in DMEM supplemented
with 10% FBS and 1% penicillin (100 units/mL) and streptomycin
(100 mg/mL) were transfected with 0.2 mg EGFR-pcDNA3 and
2 mg HA-tagged c-CBL constructs as indicated using calcium
phosphate according to manufacturer’s protocol (Profection,
Promega, Madison, WI). Twenty-four hours post-transfection,
cells were starved overnight in DMEM supplemented with 0.5%
FBS, and then treated with or without EGF (100 ng/ml) for
15 min. The cells were collected and washed two times in ice-cold
PBS containing 0.2 mM sodium orthovanadate then lysed in ice-
cold lysis buffer (10 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM
EDTA, 1% Triton X100, 10% Glycerol, 2 mM sodium
orthovanadate and protease inhibitors). Lysates were cleared of
debris by centrifugation at 16,000 g for 10 min at 4uC. EGFR
immunoprecipitations were performed on 200 mg of cleared lysate
using 250 ng of rabbit-anti-EGFR and Protein A/G Plus
Sepharose overnight at 4uC. Precipitations were washed 5 times
in lysis buffer before boiling in Laemmli buffer. Elutions were
immunoblotted with anti-ubiquitin and EGFR. Twenty micro-
grams of cleared lysate were immunoblotted for each of the c-CBL
constructs using anti-HA.
Statistical Analysis
Mutation rates between different groups were compared using
Fisher’s exact test. For continuous variables, group comparisons
were performed using analysis of variance (ANOVA) followed by
CBL Alterations in Lung Cancer
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ing repeated measurements over time were analyzed using
repeated measures ANOVA with the Greenhouse-Geisser adjust-
ment to the degrees of freedom. Analyses were conducted using
STATA (v10.1) software (Stata Corporation, College Station, TX).
Results
c-CBL Gene Mutations in Lung Cancer
To investigate the role of c-CBL in lung cancer, we analyzed its
genomic DNA in tumor and paired normal samples drawn from
multiple ethnicities. The lung tumor samples represented Cauca-
sians (n=50), African-Americans (n=29), and Taiwanese (n=40)
lung cancer patients. We designed 12 pairs of primers to sequence
the coding region of c-CBL gene that spans exons 2 to 16 (Table
S2).Weidentified8uniquesomaticmutationsinc-CBLexons among
8 differentpatients.A variationL620F,a knownSNP(rs2227988)in
exon 11 was also detected. Importantly, the eight novel non-
synonymous mutations were confirmed by sequencing both strands
of c-CBL genomic DNA obtained from lung tumor samples
(Table 1). Moreover, none of the 8 mutations were detected in
the corresponding normal tissue, indicating that these were somatic
mutations. Four synonymous single nucleotide variations (SNVs)
were also identified but were not used further in this study.
Three of the 8 novel non-synonymous mutations were located
in the TKB (tyrosine kinase binding) domain (S80N, H94Y, and
Q249E), one in the RING finger domain (V391I), one in the
proline-rich region (72515_72517 del ATG), and three in the C-
terminal region (W802*, R830K, and A848T) of the c-CBL
protein (Figure 1A and Figure S1). In Figure 1B, we show
model chromatograms of representative samples.
11q LOH of c-CBL Gene
Paired lung tumor and normal lung tissue samples from
Taiwanese patients (n=37) were investigated for LOH. Eight
(21.6%) showed LOH at the c-CBL locus on chromosome 11 while
29 samples (78.4%) revealed normal allelic contribution at the
microsatellite markers (Figures 1C and D).
c-CBL Mutations in Different Ethnic Groups
The c-CBL double mutant S80N/H94Y was found in the same
patient and the overall mutation rate for c-CBL in lung tumors
was 6.7% (8/119). The frequency of c-CBL mutation was highest
in large cell carcinoma (14.7%; 5 of 34 patients) followed by
squamous carcinoma (6.3%; 2 of 32 patients) and the least was
observed in adenocarcinoma (AD) (1.8%; 1 of 53 patients),
although these rates were not statistically significant (p=0.292).
Mutation rates were 6.0% among Caucasians (0 of 20 in AD; 0 of
10 in SQ; and 3 of 20 in LC), 13.8% in African-Americans (1 of 10
in AD; 1 of 10 in SQ; and 2 of 9 in LC), and 2.5% (0 of 23 in AD;
1 of 12 in SQ; and 0 of 5 in LC) in the Taiwanese population.
Additionally two Taiwanese patients with lung cancer (one
squamous and one adenocarcinoma) had the known SNP
L620F. Ethnic differences were not statistically significant,
however the power to detect differences was low.
Mutations in MET and EGFR Can Be Co-Associated with
c-CBL Alterations
Since East Asians with lung cancer have a higher frequency
of EGFR and MET mutations in lung tumors [21,22], we also
determined mutations in EGFR and MET in the same Taiwanese
cohort samples and compared the results with the observed c-CBL
alterations (LOH and/or mutations). In the 37 samples tested, we
did not find any overlap between c-CBL mutations and c-CBL LOH
(Figure 2). Of the three c-CBL mutants (including the known
L620F SNP, rs2227988), one of the samples had a MET mutation
(N375S)and theotherhadan EGFR mutation (L858R).Among the
8 samples that had a LOH at the c-CBL locus 5 had an additional
mutation in MET (N375S) and 2 had an EGFR exon 19 deletion.
Twenty-six samples had neither c-CBL mutation nor c-CBL LOH
(3 patients had a c-CBL mutation butno c-CBL LOH). Among these
26 samples 9 had a MET mutation (8 N375S, 1 L211W), 13 had an
EGFR mutation (7 exon 9 deletion, 6 L858R) and 4 had no other
MET or EGFR mutation. Thus the rate of MET or EGFR
mutations among patients with LOH at the c-CBL locus (7 of 8) was
similar to that seen in patients without c-CBL mutation or LOH
(22 of 26 patients) (p=0.99). These 4 patients with no identifiable
mutation in c-CBL, MET or EGFR represented 10.8% of the 37
patients analyzed in the Taiwanese patient cohort. Conversely,
89.2% Taiwanese lung cancer patients have an identifiable
mutation in either c-CBL, MET or EGFR or a combination of
the three genes (Figure 2). Additionally, we determined p53 and
KRAS mutations in these Taiwanese cohorts. Two p53 and 1 KRAS
mutation were detected. The single KRAS mutation overlappedwith
Table 1. c-CBL mutation analysis in 119 lung cancer patient tumor tissues.
Location Mutation Domain Numbers of Sample (Frequency)
Caucasian (50)
* African-American (29)* Taiwanese (40)*
Exon 2 26354 G.AG (S80N)
# TKB 1 (2%) 0 0
26395 C.CT (H94Y)
# TKB 1 (2%) 0 0
Exon 4 67885 C.CG (Q249E) TKB 0 0 1 (2.5%)
Exon 8 72104 G.AG (V391I) RING 1 (2%) 1 (3.5%) 0
Exon 9 72515_72517 del ATG Pro-rich 1 (2%) 0 0
Exon 11 79346 C.CT (L620F)
‘ Pro-rich 0 0 2 (5%)
Exon 15 92375 G.AG (W802*) C-terminal 0 1 (3.5%) 0
Exon 16 93412 G.AG (R830K) C-terminal 0 1 (3.5%) 0
93465 G.AG (A848T) C-terminal 0 1 (3.5%) 0
*( ) indicates number of samples.
# S80N and H94Y mutations were found in the same patient.
‘Known SNP.
doi:10.1371/journal.pone.0008972.t001
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8972Figure 1. c-CBL mutations and LOH in non-small cell lung cancer. (A) Schematic illustration of the various c-CBL mutants with respect to the
different functional domains. Three mutations: S80N, H94Y, Q249E were located on the TKB domain; V391I was located on the RING finger domain;
72515_72517 del ATG (a non-frameshift deletion) and L620F (a known SNP, rs2227988) were located on Pro-rich region and W802*, R830K, and A848T
were found in the C-terminal region of c-CBL. The numbers shown represent amino acid positions. Association of c-CBL mutations among different
ethnic populations is shown in the table (‘ known SNP). (B) Representative examples of sequencing chromatograms of the mutation region in
normal (N) and tumor (T) samples. Arrows indicate the heterozygous mutation in the tumor sample. (C) Loss of Heterozygosity (LOH) analysis of 37
tumor and paired normal samples from Taiwanese patients. A value of ,0.5 indicates a LOH at the c-CBL locus. (D) Schematic of Chromosome 11
markers chosen for LOH analysis and representative examples of LOH chromatogram analysis. After amplification using chromosome 11 specific
microsatellite primers, the PCR product was separated by capillary electrophoresis and bands were quantified according to the intensity.
doi:10.1371/journal.pone.0008972.g001
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but had no c-CBL mutation. The other p53 mutation sample had a
c-CBL LOH with concurrent MET N375S mutation. Thus, in the
Taiwanese samples analyzed, p53/KRAS mutations and c-CBL
mutations were mutually exclusive (data not shown).
Cellular Functions of c-CBL Alterations in the Context of
Lung Tumorigenesis
A. E3 activity is intact in the mutant c-CBL proteins. To
investigate whether the different c-CBL mutations affect the E3
activity, EGFR was chosen as a model substrate for c-CBL E3
function. All of the c-CBL mutants tested enhanced ubiquitination
of the activated EGFR similar to the wild-type c-CBL protein.
This result demonstrates that the catalytic activity of the c-CBL
mutants is not impaired when EGFR was the substrate.
(Figure 3A).
B. Effect on lung cancer cell viability. The effect of a
representative c-CBL mutant from each of the three ethnic
backgrounds on lung cancer cell viability in cell lines was
determined. S80N/H94Y double mutation, Q249E, and W802*
were identified in lung tumor samples obtained from a Caucasian,
a Taiwanese and an African-American, respectively. As described
in methods, the c-CBL wild-type (WT) and the above three
mutants were expressed after cloning them into pAlterMax vector
in A549 cells. These cells express relatively low basal levels of
endogenous c-CBL (data not shown). Transfection efficiency was
comparable between different groups and the number of cells
transfected with c-CBL wild-type construct was about 70%
compared to control cells that were transfected with the empty
vector. Cells transfected with S80N/H94Y, Q249E and W802* c-
CBL mutant constructs resulted in increased number of viable cells
that was 132.3%, 120.8% and 147.9% higher respectively, relative
to the empty vector control transfected cells and significantly
different from the wild-type construct (p=0.022, p=0.049, and
p=0.008, respectively) (Figure 3B). Relative levels of c-CBL
protein in whole cell lysates prepared from samples obtained from
a parallel experiment was determined. The c-CBL protein levels in
samples representing untransfected and empty vector transfected
cells were comparable and those representing the c-CBL WT and
the three c-CBL mutants were comparable (Figure 3C).
C. Effect on cell cycle. To investigate if the increases in cell
viability in different c-CBL mutants are due to increased cellular
proliferation, a cell cycle analysis was performed. A549 cells were
transfected with the c-CBL WT or the three different mutants:
S80N/H94Y, Q249E and W802*. The empty vector transfectant
was used as a control. Forty-eight hours after transfection cell cycle
analysis was performed as described in materials and methods.
There was no significant change in the subG1, G1 or the S phase
of the cell cycle among the different mutants compared to the WT
construct (p=0.64, p=0.40, and p=0.28, respectively). The G2/
M phase of the cell cycle showed an increase in cell numbers for
the three mutants, S80N/H94Y, Q249E and W802*, when
compared to the WT but again the difference was not statistically
significant (p=0.25) (Figure 3D).
D. Effect on cell motility. To investigate the effect of the
expression of the above three c-CBL mutants on cell migration, we
carried out wound healing assay as described in materials and
methods. The closing of the scratch or the wound was monitored
at 0, 12, 24, 36, and 48 h. (Figure 4A). In all the samples, that
represented cells transfected with mutants, the wound gap was
much smaller than that seen in the sample that represented cells
transfected with c-CBL WT (p,0.001). We also determined the
rate of wound closure for all the five groups. At 48 h, wild-type c-
CBL transfectants showed 61.1% open wound while the S80N/
H94Y, Q249E and W802* mutants showed 18.7%, 23.9% and
34.3% open wound respectively (p,0.001) (Figure 4B).
E. c-CBL knockdown increases cell viability. It is
hypothesized that the LOH seen in our samples could lead to
decreased expression of c-CBL. Thus we tested the effect of c-CBL
knockdown in lung cancer cells. Compared to A549, H358 lung
cancer cells express relatively high levels of endogenous c-CBL
(data not shown). c-CBL expression was knocked down using
lentiviral construct that expressed c-CBL specific shRNA and
compared the results with those that were transduced with
scrambled shRNA and the results are shown in Figure 5.W e
identified several clones that revealed varying degrees of c-CBL
knockdown showing different sets of c-CBL lentiviral shRNA
knockdown efficiency (Figure 5A). Of all the clones tested, Clone
27 was chosen for further experiments. Equal amount of cells were
seeded in a 6-well plate and the cell proliferation was measured at
various times and the results are depicted in Figure 5B.A s
expected, number of cells increased in a time dependent fashion
from 100 to 190% relative to scrambled shRNA as control in a
span of 48 h (p=0.0002) (Figure 5B). The cell cycle phases in
H358 cells that were knocked down with c-CBL shRNA were
looked at and compared with the scrambled shRNA. There were
no discernable differences between these two constructs in the
different phases of the cell cycle (data not shown).
Discussion
Our results demonstrate that c-CBL is somatically mutated (or
has LOH) in lung cancers, and can significantly contribute
to enhanced cell viability and motility. There was also a high
Figure 2. c-CBL mutations and relationship to MET and EGFR
mutations in lung cancer. 37 Taiwanese samples were analyzed for
mutations in c-CBL, MET and EGFR and for LOH analysis in the c-CBL
locus. Data shows 21.6% (8/37) had LOH, whereas 8% (3/37) had a c-CBL
mutation (including the known SNP L620F), these samples were
mutually exclusive. Additionally, 5 of 8 LOH samples also had MET
N375S mutation and 2 had EGFR exon 19 deletion. In the samples
having c-CBL mutation, 1 also had MET N375S mutation while another
had EGFR L858R mutation. In samples that did not harbor any c-CBL
mutation (70%, 26/37), 22 had either a MET or an EGFR mutation and
only 4 did not have a mutation in any of these 3 genes.
doi:10.1371/journal.pone.0008972.g002
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harbored MET or EGFR mutation.
In the present study, we have demonstrated the occurrence of c-
CBL mutations in lung cancer patients, especially with different
ancestral variations. Mutations in c-CBL have been recently
reported in juvenile myelomonocytic leukemia and myeloid
malignancies. In the AML study, the mutation R420Q located in
the junction of the RING finger and the linker region inhibited
FMS-like tyrosine kinase 3 (FLT3) internalization and ubiquitina-
tion [20], thus contributing to the gain-in-function for the RTK. In
addition, mutations such as H398Y, C384R, and L380P mapped to
the RING finger domain and the linker region of c-CBL that is
required for its E3 activity [23,24,25,26,27]. Additionally, homo-
zygous mutations in the RING finger domain of the c-CBL gene
were described as a result of acquired Uniparental Disomy (UPD)
[26]. It is important to note that our results indicate LOH at 11q23
locus andthese aremutually exclusive from missense mutations of c-
CBL. The somatic mutations were all heterozygous. The mutations
in AML led to abrogation of the E3 activity leading to prolonged
RTK activation. In addition mutants located on the linker region
surrounding the RING finger domain exhibited enhanced AKT
signalingin response to cytokine stimulation [26]. In addition, it was
shown in NH3T3 cells, that neither mutations in the RING finger
nor the linker region causes transformation, however while certain
mutations perturbs the ubiquitination, others affect receptor
recycling and prolong kinase activity [28].
We report here c-CBL mutations that mapped not only to the
RING finger domain, but also to the TKB domain, proline-rich
domain and the C-terminal region, but none mapped to the
linker region as reported in the AML studies described above
[23,24,25,26,29]. In addition, 8 mutants that we detected were
found in different ethnic backgrounds. For example, S80N/H94Y,
Q249E, W802* were detected in Caucasians, Taiwanese and
African-Americans, respectively. The results point out not only the
difference between lung cancer and other cancers, but also genetic
polymorphism among different races in the same cancer. Interest-
ingly, there is a large disparity between African-American and other
ethnic populations with lung cancer [30]. We have previously
shown that there was a low frequency of EGFR and MET mutation
in African-Americans as compared with Taiwanese and Caucasians
[31]. In this study, the number of African-American samples
analyzed was relatively fewer and we found 3 mutations that are
Figure 3. Ubiquitination, viability, expression and cell cycle analysis of various c-CBL mutants. (A) c-CBL mutants do not alter
ubiquitination of EGFR. Cells were co-transfected with EGFR and different c-CBL mutants were stimulated with EGF, immunoprecipitated with anti-
EGFR antibody and blotted with anti-ubiquitin antibody. Immunoblot with anti-EGFR antibody served as the IP control, while the anti-HA blot was
used as the input control. (B) Cell viability was measured by Trypan blue exclusion and compared to empty vector control. c-CBL wild-type (WT) and
mutants S80N/H94Y, Q249E, and W802* showed 66.7%, 132.3%, 120.8%, and 147.9% cell viability respectively in A549 cells 48h after transfection.
Experiments were done in triplicates and the mean data is shown. Error bars indicate Standard Deviation. (C) Protein expression levels of the various
mutants were analyzed by Western blots using c-CBL antibody. (D) Cell cycle analysis of different c-CBL mutants 48 h after transfection in A549 cells.
doi:10.1371/journal.pone.0008972.g003
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the genetic alterations that can occur and determine the targeted
therapeutics for African-Americans. Our results provide evidence of
the importance of c-CBL in tumorigenesis and potential signaling.
Our prediction, based on the AML data, would be that the V391I
RING finger domain mutation would affect the E3 activity. Also, it
willbeimportanttodeterminethebindingpartnersforc-CBLinthe
TKB domain and proline rich domain mutations. It has previously
been shown that the TKB domain can bind to growth factor
receptors and it will be important to determine the cross-binding of
these mutants to MET and or EGFR. It would also be important in
the future to look at fluorescence in situ hybridization/copy number
changes in c-CBL in lung cancer.
c-CBL plays an important role in down regulating RTK-
mediated signaling through K63 poly-ubiquitination and subse-
quent downregulation of RTKs followed by lysosomal degredation
[3]. Mono-ubiquitination or ubiquitinated with K63-linked chains
of substrates by c-CBL may lead to enhancement of biological
and biochemical functions (reviewed in Hermann et al, 2007
[32]). The mutations that we analyzed in our studies all point out
to the fact that the E3 activity of c-CBL on EGFR is intact; the
EGFR levels in the various mutants remain same (Figure S2).
Multiple kinases, both RTKs and non-RTKs could be acted
upon by c-CBL, including ERBs, PDGFR, FMS, MET, c-Kit,
VEGFR, FLT-1, RON, FGFR, IR, as well as SYK, FYN, LCK,
FGR, LYN and c-ABL [3]. In lung cancers the relevant
Figure 4. c-CBL mutations affect wound healing in A549 cells. (A) Wound healing assay was performed in A549 cells transfected with WT c-
CBL or different mutants. Empty vector (EV) was used as a control. Representative pictures (Brightfield and phase contrast) from each timepoint are
shown. (B) The open wound at each time point was quantified and normalized to 0 h. Experiments were done in triplicate and the mean data is
shown. Error bars indicate Standard Deviation.
doi:10.1371/journal.pone.0008972.g004
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are yet to be identified.
The observation that c-CBL somatic mutations, especially
S80N/H94Y, Q249E and W802* showed increased cell viability
and cell motility that is in agreement with the physiological role for
D-cbl in the regulation of apoptosis and differentiation identified
in Drosophila is very significant [33]. It has been previously shown
that activating c-CBL mutation downregulates EGFR signaling
and decreases cellular proliferation and migration in breast
cancer cell lines [34]. Although the role of c-CBL in the negative
regulation of RTKs is well substantiated, thereby suggesting that it
is a natural tumor suppressor, studies in cancer cells have revealed
both tumor suppressor and tumor promoting activities depending
on the type of c-CBL mutation and the number of alleles at the c-
CBL locus [24]. In agreement with the above, the three c-CBL
mutants described here appear to have tumor growth and
metastasis promoting properties. Although these mutants are
outside of the RING finger or the linker region of c-CBL, their
downstream effects are significant so as to cause increased
proliferation and migration, but the substrate affected by these
mutations are not known yet. This raises the possibility that some
of the cellular functions of c-CBL are independent of its ubiquitin-
ligase activity, an area that we are currently investigating. The
oncogenic nature of RTKs, addiction of cancers to growth signals
and given the clustering of c-CBL, EGFR and MET mutations, it is
possible that the transforming effect of c-CBL mutations is most
likely a combinatorial effect of the three. We also show that LOH
for c-CBL was found in a significant number of samples that
harbored MET or EGFR mutations. The fact that about 7% of
lung tumor samples are likely to have c-CBL mutations and an
additional 22% are likely to harbor c-CBL-related LOH, makes c-
CBL a highly mutated molecule in lung cancer. Since LOH alone
is not enough to cause a transforming event [35,36,37], associated
mutation in the MET or EGFR locus or yet another RTK
discussed above may play a role in carcinogenesis. We predict that
this LOH in c-CBL results in haploinsufficiency that down-
plays RTK ubiquitination leading to hyperactivity of the RTKs.
However, whether this is sufficient cause for tumorigenesis remains
to be determined. Consistent with our hypothesis is the fact that
c-cbl
-/- mice have increased kinase activity in lymphocytes, but is
not sufficient for tumor formation [35,36,37]. c-CBL LOH could
also lead to increased expression of c-CBL from the other allele to
compensate for a loss of an allele. Alternately, there could be some
form of synergy working with reduced c-CBL levels and mutated
receptors that exacerbate the phenotype of each alone.
Previous studies from our lab and others have shown that East
Asians with lung cancers have relatively high frequencies of gain-
of-function of mutations in RTKs such as EGFR and MET [31].
In a cohort of Japanese patients an activating MET mutation was
identified in the splice region that deletes the juxtamembrane
domain that is involved E3 activity of c-CBL [38]. This study also
found that activation of MET is mutually exclusive of EGFR,
KRAS and HER2 gene mutations [38]. We failed to detect such
mutations in significant numbers in lung tumor samples obtained
from African-Americans (n=29) and Caucasian (n=50) patients.
One MET mutation was identified in each of the groups whereas 1
and 3 EGFR mutations were identified in the African-American
and Caucasian cohorts respectively. EGFR mutations have earlier
been identified as one of the key mutations affecting lung
adenocarcinoma patients in a comprehensive study of 188 patients
[39]. Our study encompasses different histologies of NSCLC.
However, the published series did not find any mutations in c-CBL
or MET unlike our study that encompassed different subtypes of
NSCLC. It is important to note, we have recently shown that
MET mutations in lung cancer are in majority germline [31]. We
have reported earlier c-CBL mutations in a small cohort of
Taiwanese lung cancer samples [40]. In our efforts to understand
the ethnic differences in the lung oncogenome, we also looked at
PAX transcription factors such as PAX5 and PAX8 that are highly
expressed in lung cancers; however there was no preferential
expression or mutations of the above genes in lung tumor samples
of African-Americans. In this study, we show relatively high
frequency of c-CBL mutations in lung cancers, especially in the
large cell type among Caucasians and particularly among African-
Americans. We therefore propose c-CBL as an efficacious target
for lung cancers in African-Americans that needs to be further
substantiated. This is all the more important because the prognosis
for African-Americans with lung cancer, especially for men is
much poorer compared to their Caucasian counterparts [41].
In conclusion, the results presented in this study demonstrate that
c-CBL is frequently mutated or even lost in lung cancers. Our
results support a role for c-CBL mutants that are independent of its
ubiquitination activity. Given the relativelyhigh mutation rates in c-
CBL as well as RTKs such as MET and EGFR, it is likely that their
combined effect could be synergistic in promoting tumorigenesis.
Supporting Information
Figure S1 Schematic of c-CBL domains and associated exons.
Numbers at the top indicate amino acid residues flanking the domains.
Found at: doi:10.1371/journal.pone.0008972.s001 (0.42 MB TIF)
Figure S2 Western blot showing EGFR levels in different c-CBL
mutants used in the study. EGFR levels were relatively unchanged
among the three mutants compared to wild-type c-CBL. b-actin
was used as a loading control.
Found at: doi:10.1371/journal.pone.0008972.s002 (3.00 MB TIF)
Table S1 Number of samples analyzed in patients by race and
sub-type of lung cancer.
Found at: doi:10.1371/journal.pone.0008972.s003 (0.03 MB
DOC)
Figure 5. Knockdown of c-CBL using an shRNA increases cell
proliferation. (A) Western blots of different c-CBL shRNA constructs
showing knockdown efficiency of different clones. Scrambled shRNA
was used as a control. (B) Lung cancer cell line H358 stably transfected
with shRNA clone 27 showed an increase in cell counts compared to the
scrambled shRNA control. Experiments were done in triplicates and the
mean data is shown. Error bars indicate Standard Deviation.
doi:10.1371/journal.pone.0008972.g005
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